Results 11 to 20 of about 25,024 (228)

Paroxetine Attenuates Chondrocyte Pyroptosis and Inhibits Osteoclast Formation by Inhibiting NF-κB Pathway Activation to Delay Osteoarthritis Progression

open access: yesDrug Design, Development and Therapy, 2023
Xiaohang Zheng,1,2 Jianxin Qiu,1,2 Ning Gao,3 Ting Jiang,1,2 Ze Li,1,2 Weikang Zhang,1,2 Yuhang Gong,1,2 Zhenghua Hong,1,2 Huaxing Hong1,2 1Orthopedic Department, Taizhou Hospital Affiliated to Wenzhou Medical University, Linhai, People’s Republic of ...
Zheng X   +8 more
doaj   +1 more source

Comparative effectiveness of switching paroxetine formulation for treatment of major depressive disorder: an open-label multicenter study

open access: yesNeuropsychiatric Disease and Treatment, 2018
Tempei Otsubo,1 Yoshinori Watanabe,2,3 Seiji Hongo,3 Mikichika Inoue,4 Kimiko Akimoto,4 Ken Murakami,5 Ryutaro Takahashi,6 Toshiaki Kikuchi7 1Department of Psychiatry, Tokyo Women’s Medical University Medical Center East, Tokyo, Japan; 2Himorogi ...
Otsubo T   +7 more
doaj   +1 more source

Highly Enantioselective Synthesis of Functionalized Glutarimide Using Oxidative N‑Heterocyclic Carbene Catalysis: A Formal Synthesis of (−)-Paroxetine

open access: yes, 2019
A simple yet highly effective approach toward enantioselective synthesis of trans-3,4-disubstituted glutarimides from readily available starting materials is developed using oxidative N-heterocyclic carbene catalysis.
Joyram Guin (1993765)   +2 more
core   +4 more sources

Inhibition of G Protein-Activated Inwardly Rectifying K+ Channels by the Antidepressant Paroxetine

open access: yesJournal of Pharmacological Sciences, 2006
Paroxetine is commonly used as a selective serotonin reuptake inhibitor for the treatment of depression and other psychiatric disorders. However, the molecular mechanisms of the paroxetine effects have not yet been sufficiently clarified.
Toru Kobayashi   +2 more
doaj   +1 more source

Paroxetine overdose during pregnancy

open access: yesForensic Sciences Research, 2021
Paroxetine is a selective serotonin reuptake inhibitor (SSRI) used in the treatment of depression and anxiety disorders. In some epidemiological studies, slightly increased risks of major malformations and cardiac malformations have been reported ...
Selin Acar   +6 more
doaj   +1 more source

Anti-proliferative effects of paroxetine alone or in combination with sorafenib in HepG2 cells

open access: yesBrazilian Journal of Pharmaceutical Sciences, 2023
Hepatocellular carcinoma (HCC) is a common cause of cancer-related death. Sorafenib is the first approved drug for the treatment of advanced HCC. Depression is frequent in cancer patients.
Yaprak Donmez Cakil   +4 more
doaj   +1 more source

Paroxetine in the treatment of premature ejaculation: a systematic review and meta-analysis

open access: yesBMC Urology, 2019
Background Paroxetine is one of the selective serotonin reuptake inhibitors (SSRIs) used in the treatment of premature ejaculation (PE). However, this use is not approved in many countries.
Dong Zhang   +5 more
doaj   +1 more source

Paroxetine suppresses reactive microglia-mediated but not lipopolysaccharide-induced inflammatory responses in primary astrocytes

open access: yesJournal of Neuroinflammation, 2020
Background Astrocytes are the most abundant glial cells in a brain that mediate inflammatory responses and provide trophic support for neurons. We have previously disclosed that paroxetine, a common selective serotonin reuptake inhibitor, ameliorates LPS-
Xiong Zhang   +8 more
doaj   +1 more source

A Randomized Double-blind Placebo-controlled Trial to Assess the Effect of Tamarind seed in Premature Ejaculation

open access: yesAdvanced Biomedical Research, 2018
Background: This randomized clinical trial was aimed to evaluate the effect of oral use of tamarind seed powder as an herbal product in patients affected by premature ejaculation (PE).
Abdulla Homayuonfar   +5 more
doaj   +1 more source

GRK2 inhibitors, paroxetine and CCG258747, attenuate IgE-mediated anaphylaxis but activate mast cells via MRGPRX2 and MRGPRB2

open access: yesFrontiers in Immunology, 2022
G protein-coupled receptor (GPCR) kinase 2 (GRK2), which phosphorylates agonist-occupied GPCRs to promote their desensitization, has been investigated as an attractive therapeutic target for cardiovascular and metabolic diseases.
Monica Thapaliya   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy